Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.
Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.